Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update
- PMID: 24663048
- DOI: 10.1200/JCO.2013.54.1177
Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update
Abstract
Purpose: To provide evidence-based recommendations to practicing oncologists, surgeons, and radiation therapy clinicians to update the 2005 clinical practice guideline on the use of sentinel node biopsy (SNB) for patients with early-stage breast cancer.
Methods: The American Society of Clinical Oncology convened an Update Committee of experts in medical oncology, pathology, radiation oncology, surgical oncology, guideline implementation, and advocacy. A systematic review of the literature was conducted from February 2004 to January 2013 in Medline. Guideline recommendations were based on the review of the evidence by Update Committee.
Results: This guideline update reflects changes in practice since the 2005 guideline. Nine randomized clinical trials (RCTs) met systematic review criteria for clinical questions 1 and 2; 13 cohort studies informed clinical question 3.
Recommendations: Women without sentinel lymph node (SLN) metastases should not receive axillary lymph node dissection (ALND). Women with one to two metastatic SLNs planning to undergo breast-conserving surgery with whole-breast radiotherapy should not undergo ALND (in most cases). Women with SLN metastases who will undergo mastectomy should be offered ALND. These three recommendation are based on RCTs. Women with operable breast cancer and multicentric tumors, with ductal carcinoma in situ (DCIS) who will undergo mastectomy, who previously underwent breast and/or axillary surgery, or who received preoperative/neoadjuvant systemic therapy may be offered SNB. Women who have large or locally advanced invasive breast cancer (tumor size T3/T4), inflammatory breast cancer, or DCIS (when breast-conserving surgery is planned) or are pregnant should not undergo SNB. These recommendations are based on cohort studies and/or informal consensus. In some cases, updated evidence was insufficient to update previous recommendations.
Comment in
-
Axillary treatment in women with one or two sentinel nodes with macrometastases: more evidence is needed to inform practice.J Clin Oncol. 2014 Dec 1;32(34):3902. doi: 10.1200/JCO.2014.57.3717. Epub 2014 Sep 22. J Clin Oncol. 2014. PMID: 25245444 No abstract available.
-
Recommendation for omitting axillary lymph node dissection should be individualized in patients with breast cancer with one or two positive sentinel lymph nodes.J Clin Oncol. 2014 Dec 1;32(34):3901-2. doi: 10.1200/JCO.2014.57.1190. Epub 2014 Sep 22. J Clin Oncol. 2014. PMID: 25245448 No abstract available.
-
Reply to I.A. Voutsadakis et al and A. Goyal et al.J Clin Oncol. 2014 Dec 1;32(34):3902-4. doi: 10.1200/JCO.2014.57.7361. Epub 2014 Sep 22. J Clin Oncol. 2014. PMID: 25245450 No abstract available.
-
Is the Current American Society of Clinical Oncology Guidance on Axillary Management Generalisable for Symptomatic or Unscreened Breast Cancers?Clin Oncol (R Coll Radiol). 2017 Oct;29(10):e172-e173. doi: 10.1016/j.clon.2017.06.004. Epub 2017 Jun 28. Clin Oncol (R Coll Radiol). 2017. PMID: 28666763 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
